Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226262 | 0.88 | — | — | |
| SCHEMBL18526419 | 0.78 | METAP1 (0.47) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10597079 | 0.77 | IDO1 (0.37) | CTSKPTGER4PTGER3PTGER2 | |
| SCHEMBL9575838 | 0.77 | IDO1 (0.37) | CTSKPTGER4PTGER3PTGER2 | |
| SCHEMBL8901183 | 0.77 | IDO1 (0.34) | PTGER4PTGER3PTGER2 | |
| SCHEMBL9575583 | 0.77 | IDO1 (0.37) | CTSKPTGER4PTGER3PTGER2 | |
| SCHEMBL9450427 | 0.77 | IDO1 (0.37) | CTSKPTGER4PTGER3PTGER2 | |
| SCHEMBL13723044 | 0.76 | ADH1B (0.43) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6085440 | 0.74 | IDO1 (0.32) | PTGER4PTGER3PTGER2 | |
| SCHEMBL9575433 | 0.74 | IDO1 (0.35) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | SHAPIRO STANLEY S (US) | 2012-02-02 | — | — | US | claimed |
| JP-4401441-B2 | — | — | 2010-01-20 | — | — | JP | claimed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | claimed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | claimed |
| EP-0886647-B1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL NV (NL) | 2002-07-24 | — | — | EP | claimed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | claimed |
| JP-2001502360-A | — | — | 2001-02-20 | — | — | JP | claimed |
| EP-0948308-A1 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999004752-A9 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER (US) | 1999-04-08 | — | — | WO | claimed |
| CN-1212705-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | claimed |
| WO-1999004752-A2 | METHODS FOR TREATING SKIN PIGMENTATION | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| CN-1192747-A | Peptidyl heterocyclic compounds for the treatment of thrombin-related diseases | ORTHO PHARMA CORP (US) | 1998-09-09 | — | — | CN | claimed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | claimed |
| CN-1234735-B | Use of soybean trypsin inhibitors affecting the PAR-2 pathway to affect changes in skin pigmentation | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027706-A1 | METHODS FOR TREATING SKIN PIGMENTATION | TYR, MC1R, NQO1 | ADH1B 52/4885ADH1C 3779/4885ADH1A 3616/4885 |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | ADH1B 731/4885ADH1C 4680/4885ADH1A 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.